Incyte pulled the plug on several Jakafi studies as the blood cancer therapy proved less effective in solid tumors when used solo. The company still sees potential in the field with Jakafi cocktails, including combos that pair the med with immuno-oncology meds. Jakafi is marketed outside the U.S. by Novartis, which brought in $410 million from the drug last year; Incyte's U.S. sales amounted to $601 million.
Hemovent has raised a $6 million Series A financing to support the development of what it expects will be the world's smallest and first self-contained and fully portable Extra Corporeal Membrane Oxygenation (ECMO) system to support or replace heart and lung function.
Regentis Biomaterials has raised a $15 million Series D round from investors led by Chinese biopharma Haisco Pharmaceutical Group. The Israeli cartilage repair company will use the financing to conduct a U.S. pivotal trial of its GelrinC, which is implanted as a liquid and forms into a resorbable implant that is ultimately replaced by newly regenerated cartilage.
Pfizer's planned $160 billion merger with Allergan has some researchers worried the company will embrace its counterpart's austere approach to R&D and mount major layoffs.
GlaxoSmithKline's flu vaccines, Fluarix and FluLaval, are both egg-based and can take months to produce each year. Now, the company has signed a pair of research deals, one of which would allow it to make cell-based vaccines, which are more efficient to manufacture.
As the Zika virus continues to spread, more biotechs are announcing their Zika vaccine programs. Meriden, CT-based Protein Sciences, Atlanta-based GeoVax Labs and Redwood City, CA-based PaxVax are the latest. PaxVax plans to bring its candidate to animal trials during the first half of this year, CEO Nima Farzan told FierceVaccines.
Novartis has been riding a med tech wave lately, launching new projects to create digital and patient-monitoring devices. In its latest move, the company is working with tech giant Microsoft to develop an intelligent camera system for multiple sclerosis (MS).
Researchers at Philadelphia's Drexel University have developed a microscopic "crystal ball" that could someday be used for drug delivery.
Several drug delivery devices are on a draft list of med tech that will be subject to a final guidance calling for the application of human factors and usability engineering to medical devices.
The U.K.'s National Health Service hasn't exactly earned high marks so far for its efforts on the digital health front. Its prior efforts to convert to electronic medical records have failed. But the health program is redoubling its efforts now by committing £4.2 billion ($6 billion) to a variety of digital health initiatives. That news comes on the heels of the agency announcing a series of 7 med tech-focused trials with major technology partners including Alphabet's Verily, Royal Philips and Accenture.